Touro Scholar
NYMC Faculty Publications

Faculty

6-1-2018

Cortical GABAergic Interneuron/Progenitor Transplantation as a
Novel Therapy for Intractable Epilepsy
Qian Zhu
New York Medical College

Janice R. Naegele
Sangmi Chung
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Zhu, Q., Naegele, J., & Chung, S. (2018). Cortical GABAergic Interneuron/Progenitor Transplantation as a
Novel Therapy for Intractable Epilepsy. Frontiers in Cellular Neuroscience, 12, 167. https://doi.org/
10.3389/fncel.2018.00167

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

MINI REVIEW
published: 26 June 2018
doi: 10.3389/fncel.2018.00167

Cortical GABAergic
Interneuron/Progenitor
Transplantation as a Novel Therapy
for Intractable Epilepsy
Qian Zhu 1 , Janice R. Naegele 2* and Sangmi Chung 1*
1

Translational Stem Cell Neurobiology Laboratory, Department of Cell Biology and Anatomy, New York Medical College,
Valhalla, NY, United States, 2 Hall-Atwater Laboratory, Department of Biology, Program in Neuroscience and Behavior,
Wesleyan University, Middletown, CT, United States

Edited by:
Jan Tønnesen,
Achucarro Basque Center
for Neuroscience, Spain
Reviewed by:
Luiz E. Mello,
Federal University of São Paulo, Brazil
Qing Yun Wang,
Beihang University, China
*Correspondence:
Janice R. Naegele
jnaegele@wesleyan.edu
Sangmi Chung
schung8@nymc.edu;
sangmichung@gmail.com
Received: 31 January 2018
Accepted: 30 May 2018
Published: 26 June 2018
Citation:
Zhu Q, Naegele JR and Chung S
(2018) Cortical GABAergic
Interneuron/Progenitor
Transplantation as a Novel Therapy
for Intractable Epilepsy.
Front. Cell. Neurosci. 12:167.
doi: 10.3389/fncel.2018.00167

Epilepsy is a severe neurological disease affecting more than 70 million people
worldwide that is characterized by unpredictable and abnormal electrical discharges
resulting in recurrent seizures. Although antiepileptic drugs (AEDs) are the mainstay of
epilepsy treatment for seizure control, about one third of patients with epilepsy suffer
from intractable seizures that are unresponsive to AEDs. Furthermore, the patients
that respond to AEDs typically experience adverse systemic side effects, underscoring
the urgent need to develop new therapies that target epileptic foci rather than more
systemic interventions. Neurosurgical removal of affected brain tissues or implanting
neurostimulator devices are effective options only for a fraction of patients with drugrefractory seizures, so it is imperative to develop treatments that are more generally
applicable and restorative in nature. Considering the abnormalities of GABAergic
inhibitory interneurons in epileptic brain tissues, one strategy with considerable promise
is to restore normal circuit function by transplanting GABAergic interneurons/progenitors
into the seizure focus. In this review, we focus on recent studies of cortical GABAergic
interneuron transplantation to treat epilepsy and discuss critical issues in moving this
promising experimental therapeutic treatment into clinic.
Keywords: intractable epilepsy, GABAergic interneurons, cell transplantation, animal models, human pluripotent
stem cells, differentiation

INTRODUCTION
Epilepsy is a serious and chronic brain disorder that affects more than 70 million people
worldwide (Singh and Trevick, 2016). The fundamental characteristics of epilepsy include
recurrent seizures and loss of consciousness caused by unpredictable and abnormal electrical
discharges (Baraban et al., 2009; Yuan et al., 2011). The etiology of epilepsy is complicated
and heterogenous, including structural, genetic, infectious, metabolic, immune and/or other
unknown causes (Scheffer et al., 2017). Currently, epilepsies are classified into focal epilepsies,
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refractory epilepsy, call for the development of more effective and
restorative therapeutics.

generalized epilepsies, combined generalized and focal epilepsies,
and unknown epilepsies based on the types of seizures the
patients display (Fisher, 2017; Fisher et al., 2017; Scheffer et al.,
2017). In various etiologies and manifestations of epilepsies,
more than 30% of cases are comprised of refractory epilepsies
in which medical therapies fail to manage the seizures (Engel,
2014), presenting an urgent, unmet need for new treatments. In
this review, we will discuss the promise of neuronal cell-based
transplantation therapies for epilepsy as a novel and restorative
therapy.

CORTICAL GABAergic INTERNEURONS
IN NORMAL AND EPILEPTIC BRAINS
In the neocortex, excitatory pyramidal cells comprise 70–
80% of neurons, while interneurons, mostly inhibitory
interneurons, constitute the remaining 20–30% (Markram et al.,
2004). Although inhibitory interneurons releasing GammaAminobutyric Acid (GABA) are far fewer than excitatory
pyramidal neurons, they serve critical roles in regulating activity
within brain circuits (Buzsáki et al., 2007). During early brain
development, cortical GABAergic interneurons primarily
arise from Medial Ganglionic Eminence (MGE) and Caudal
Ganglionic Eminence (CGE), and migrate tangentially over long
distances to their final destinations in the cerebral cortex where
they form local inhibitory synaptic connections with excitatory
pyramidal neurons and other GABAergic interneurons (Kelsom
and Lu, 2013; Tyson and Anderson, 2014; Hunt and Baraban,
2015). These interneuron progenitors from MGE and CGE
generate strikingly diverse subtypes of neurons, classified by their
morphology, physiology and molecular properties (Markram
et al., 2004).
Interneuron abnormalities have been observed in various
cases of epilepsy, especially for those that were derived from
MGE. In a non-human primate model of neocortical focal
epilepsy, a dramatic decrease was observed in the number
of GABAergic symmetric synapses in epileptic foci (Ribak
et al., 1982). In tissue from patients with temporal lobe
epilepsy (TLE), hippocampal seizure foci were characterized
by the loss of somatostatin (SST)+ interneurons (de Lanerolle
et al., 1989). In a rodent model of TLE, key features include:
altered interneuron firing, reduced numbers of inhibitory
interneurons, initial loss of inhibitory synapses followed by
synaptic sprouting and alterations in GABAA receptors (Sloviter,
1987; Scharfman, 1999; Kobayashi and Buckmaster, 2003;
Scharfman and Myers, 2013; Chohan and Moore, 2016). With
consistent observations of interneuron abnormalities in seizure
foci, hypofunction/degeneration of GABAergic interneurons has
been hypothesized to be key to the neural circuit dysfunction
that underlies epileptogenesis and the development of recurrent
spontaneous seizures (Buckmaster et al., 2002; Goldberg and
Coulter, 2013; Southwell et al., 2014; Hunt and Baraban, 2015).
In line with this hypothesis, it was shown that epilepsyrelated loss of hilar SST+ interneurons resulted in reduced
dentate gyrus inhibition (Hofmann et al., 2016). Furthermore,
rapid optogenetic stimulation of hippocampal parvalbumin
(PV)+ interneurons effectively suppressed spontaneous seizures
(Armstrong et al., 2013; Krook-Magnuson et al., 2013),
pointing to the efficacy of modulating GABAergic inhibition for
therapeutic purposes.
Unlike cortical GABAergic interneurons derived from MGE,
cortical GABAergic interneurons originating in the embryonic
CGE, are comprised chiefly of Calretinin (CR)+ and Vasoactive
Intestinal Polypeptide (VIP)+ expressing subtypes; these

CURRENT TREATMENT FOR EPILEPSY
Antiepileptic drugs (AEDs) are the mainstay of epilepsy
treatments for controlling seizures (Goodwin, 2005) and they
are cost-effective choices for most individuals with epilepsy.
However, patients responding well to AEDs typically experience
adverse systemic side effects, such as skin rashes, mental slowing,
visual side effects, and behavioral disorders (Walia et al., 2006).
For example, phenobarbital, which is one of the oldest AEDs, is
associated with significant adverse events which may dramatically
affect the quality of patients’ life (Baram and Shinnar, 2002).
However, it is still widely prescribed because of its low cost
and broad spectrum efficacy for multiple seizure types (Pal,
2007), By contrast, levetiracetam is one of the newer AEDs
that has less severe side effects with higher tolerability, but
its monthly cost is substantially higher (Hovinga, 2001; Ho
et al., 2018). In addition, about one-third of patients that do
not respond to any AEDs have to live with intractable seizures
(Herman, 2010). Drug-resistant seizures can be potentially lifethreatening and are associated with psychological impairments,
excessive body injuries, and compromised quality of life
(Sperling, 2004; Laxer et al., 2014). These disadvantages of
AEDs underscore the need for alternate therapeutics that target
epileptic foci.
Two alternatives are neurosurgical resection of the seizure
focus (Kneen and Appleton, 2006) and neurostimulation (Lin
and Wang, 2017). Compared to current drug therapies, patients
that undergo surgical removal of seizure foci are more likely to
become seizure free with better quality of life (Liu et al., 2018).
However, surgical resection is a costly procedure, and can only be
done successfully when the seizure focus can be clearly identified
and safely removed without lasting consequences (Bertram,
2014; Jobst and Cascino, 2015). Moreover, many patients relapse
after an initial seizure-free phase (de Tisi et al., 2011). The
major advantages of neurostimulation over surgical resections
and AEDs are that this approach does not require removal
of brain tissue, and it can be applied into a specific target
region to modulate affected neural circuity (Lin and Wang,
2017). Electrical neurostimulation is reported to be effective and
acceptably safe (Heck et al., 2014), but it is currently useful
only in a fraction of patients with drug-refractory seizures
(Pais-Vieira et al., 2016). Transcranial magnetic stimulation is
non-invasive, but there is no powerful evidence to support its
efficacy (Lin and Wang, 2017). These limitations in the currently
available treatment options for epilepsy, especially for those for
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dentate granule cells could provide a mechanism for seizure
suppression in the TLE mice. Unconventionally, Chu et al.
(2004) injected that human neural stem cells intravenously
in adult rats with TLE, and observed that injected stem
cells migrated to the damaged hippocampus, differentiated
into GABAergic interneurons, and reduced seizures, warranting
further exploration of this non-invasive cell delivery method
to a damaged seizure focus. In addition to fetal-derived
interneuron progenitors, Maisano et al. (2012) studied the effects
of transplanting GABAergic interneurons derived from mouse
embryonic stem cells into the dentate gyrus of mice with
pilocarpine-induced TLE, and showed that these interneurons
can functionally integrate the host brain circuitry and develop
mature electrophysiological firing patterns characteristic of
endogenous hippocampal interneurons.
In addition to more well-defined seizure foci as in TLE, MGE
progenitor cells have also been transplanted to the neocortex to
prevent seizures or elevate seizure thresholds. Transplantation of
mouse fetal MGE cells into the neonatal mouse neocortex was
effective in reducing the frequency and duration of seizures in
a genetic model of epilepsy (Baraban et al., 2009). Although the
transplants did not migrate throughout the entire cortical areas
affected by Kv1.1 mutation, increasing inhibition in a limited area
of the developing neocortex was enough to ameliorate seizures in
these mice. Transplants of mouse fetal MGE cells also reduced
seizure susceptibility and spread in an acute model of epilepsy
induced by maximum electroconvulsive shock (Calcagnotto
et al., 2010). Additionally, in stargazer mutant mice, which show
spike and wave discharges resembling absence seizures (AE),
transplanting fetal mouse MGE cells into the occipital neocortex
reduced AE episodes and modified defective cortical network
activity (Hammad et al., 2014). Taken together, these studies of
GABAregic progenitor transplantation show that multiple graft
locations, in both adult and developmental models of epilepsy,
can suppress seizures or raise seizure thresholds. Further work
is needed to define which sites provide the most effective seizure
suppression for each seizure model.
Harvesting large numbers of MGE precursors from human
embryos for clinical applications is impractical and raises ethical
concerns, whereas differentiation of sufficient numbers of MGE
progenitor cells from human pluripotent stem cells (PSCs),
including human embryonic stem cells (hESCs) and human
induced pluripotent stem cells (hiPSCs), is becoming more
routine in many scientific laboratories (Goulburn et al., 2011;
Germain et al., 2013; Liu et al., 2013a; Maroof et al., 2013;
Nicholas et al., 2013; Kim et al., 2014). After transplantation
into mouse brains, hPSC-derived MGE progenitors gradually
mature into functional GABAergic interneurons and become
synaptically integrated into host brain circuits (Nicholas et al.,
2013; Kim et al., 2014). Most importantly, transplantation of
human PSC-derived MGE cells into the hippocampus was
efficacious in the pilocarpine model of TLE (Cunningham
et al., 2014). In this study, Cunningham et al. (2014) showed
that human PSC-derived MGE progenitors migrated robustly
and developed into functional GABAergic interneurons that
integrated into the neural circuitry of the host brain, suppressed
seizure activity, and corrected behavioral abnormalities, such

subtypes are not ideal for transplantation to control seizures,
since they mostly target other interneurons over excitatory
pyramidal neurons, and are thought to disinhibit neural circuits,
which might lead to hyperexcitability (Pi et al., 2013; Hunt and
Baraban, 2015; Pelkey et al., 2017).

GABAergic
INTERNEURON/PROGENITOR
TRANSPLANTATION TO TREAT
EPILEPSY
In the pioneering studies, transplantation of noradrenergic
neurons was reported to suppress seizures in several different
models of epilepsy (Barry et al., 1987; Bengzon et al., 1990;
Bortolotto et al., 1990). However, considering the preponderance
of interneuron pathologies in TLE, more recent studies have
focused on transplanting GABAergic interneurons/progenitors
into seizure foci. Preclinical studies in animal models of epilepsy
have shown the efficacy of GABAergic interneuron/progenitor
transplantation in ameliorating seizures (Löscher et al., 1998;
Hattiangady et al., 2008; Baraban et al., 2009; Calcagnotto et al.,
2010; Handreck et al., 2012; Maisano et al., 2012; Hunt et al., 2013;
Cunningham et al., 2014; Hammad et al., 2014; Henderson et al.,
2014; Table 1). Pioneering work by Löscher et al. (1998) revealed
that transplanting rat fetal GABAergic neurons into the substania
nigra (SN) led to a dramatic increase in afterdischarge thresholds
and significant reductions in the severity of seizures. Although
this anticonvulsant effect was not long-lasting, it did not cause
adverse effects (Löscher et al., 1998). In 2012, Handreck et al.
observed the anticonvulsant effects of GABA-producing cells
implanted bilaterally/unilaterally into the subthalamic nucleus
(STN) using a pentylenetetrazole (PTZ)-induced acute seizure
model in adult rats. In addition, they observed that grafting
into the STN caused more pronounced anticonvulsant effects
than grafting into the SN (Handreck et al., 2012). In these
two studies, GABA-producing cells were placed into sites that
modulate seizures rather than the seizure focus. In future studies,
it will be important to compare and determine the optimal sites
for cell delivery for each type of seizure, whether it is within the
seizure focus or in seizure-modulating loci.
More studies on cell therapy for epilepsy have directly
targeted the seizure focus to replenish dysfunctional or damaged
GABAergic interneurons, especially for TLE models in rodents.
Hattiangady et al. demonstrated that bilateral grafting of
interneuron progenitors into the hippocampus reduced the
frequency of spontaneous seizures on a long-term basis
(Hattiangady et al., 2008). In the same line, Hunt et al. (2013)
and Henderson et al. (2014) reported that spontaneous seizures
could be controlled by grafting mouse fetal MGE cells into the
hippocampus of TLE mice, but not the amygdala nor entorhinal
cortex. By optogenetic stimulation of the transplanted MGE cells,
Henderson et al. (2014) further showed that the new inhibitory
synaptic connections formed onto dentate granule cells were
capable of inducing strong postsynaptic inhibition, suggesting
that increased synaptic inhibition from the transplants onto
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Mouse

Mouse

Mouse

Mouse
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Baraban
et al., 2009

Calcagnotto
et al., 2010

Maisano
et al., 2012

Hunt et al.,
2013

Henderson
et al., 2014
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Pilocarpine-induced TLE model
in adult mice

Pilocarpine-induced TLE model
in adult mice (P51)

MGE cells from E13.5 GFP+
mouse embryos

MGE cells from E 13.5
VGAT-Venus or
VGAT-ChR2-EYPF transgenic
embryos

Pilocarpine-induced TLE model
in adult mice

Mouse embryonic stem
cell-derived neural progenitors

An acute epileptic seizure
model induced by MES
2 months after transplantation

Kv 1.1−/− mutant mice (a
spontaneous seizure model of
generalized epilepsy)

MGE cells from E13.5 GFP+
transgenic mice

MGE cells from mouse
embryos

Animal models of epilepsy

Cell type

• The frequency and duration of tonic seizures were reduced in the MGE
group when compared to the control group
• The mortality rate was also significantly decreased in the MGE group,
compared to the control group
• The grafted MGE cells migrated and differentiated into GABAergic
interneurons

• MGE progenitors generated multiple GABAergic interneuron subtypes in the
brain
• The frequency and duration of spontaneous seizures was reduced after
MGE cell grafting

Results of transplantation

Bilateral injections into the hilus
of the DG or the LEC of mice
2 weeks following SE

Bilateral injection of MGE cells
into the hippocampus or
amygdala of adult mice
(P60-76)

(Continued)

•The DG transplant group showed significantly fewer generalized seizures
than controls, based on EEG recordings and behavioral assessment.
• MFS in the vicinity of MGE grafts in the dorsal hippocampus was significantly
reduced in the DG transplant group, compared with the media control group
and the LEC transplant group
• MGE cells differentiated into different subtypes of GABAergic interneurons
• Synaptic inhibition onto granule cells was increased in the DG transplant
group compared to the media control group and the dead cell transplant
group
• Extensive inhibitory synaptic network with granule cells was established, and
these new synapses were shown by optogenetics to provide functional
synaptic inhibition of granule cells

In the hippocampus
In the amygdala
• MGE progenitors dispersed and • MGE progenitors were present in
differentiated into functionally
the basal and lateral nuclei
integrated mature GABAergic
• Seizure frequency was not altered
interneurons
• Only the hyperactivity deficit was
• The occurrence of
reversed. Other behavior deficits
electrographic seizures was
were not improved
reduced
• Neurobehavioral comorbidities
including aggressive reaction to
handling, hyperactivity and
spatial learning were restored

Bilateral transplantation into the • The majority of the grafted cells differentiated into multiple subtypes of
hilus of the DG of mice 2 weeks
GABAergic interneurons
following SE
• Extensive axonal projections were formed in the brain, although marked
suppression of MFS was not observed
• The majority of the transplanted cells exhibited electrophysiological
properties, morphologies and firing patterns consistent with endogenous
hippocampal interneurons
• The transplanted cells were functionally integrated into the host brain
circuitry

Bilateral transplantation into the
neocortex of neonatal normal
mice

Bilateral transplantation into
deep layers of cortex in mouse
pups (P1-P3)

Location and timing of
transplantation

TABLE 1 | A summary of GABAergic interneuron/progenitor transplantation in animal models of epilepsy.
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MGE cells derived from hESCs

Genetically engineered
GABA-producing cell lines:
(1) Immortalized GABAergic
cells (M213-2O)
(2) M213-2O hGAD67 cells

Striatal progenitors from E15 rat
embryo LGE

Fetal striatal GABAergic
neurons from E14 rats

MGE cells from E12.5 GFP
mice

Cell type

Pilocarpine-induced TLE model

An acute seizure model by
using the timed intravenous
PTZ infusion seizure test.
PTZ seizure thresholds were
determined at 2–3 days before
transplantation, and different
time points after transplantation
(10–11 days, 3 weeks, and
5 weeks).

A SE model of chronic TLE in
adult rats induced by graded
intraperitoneal injections of
kainic acid

A kindling model of TLE by
electrical stimulation from a
bipolar electrode implanted in
the basolateral amygdala

A Stargazer mouse model of
AE

Animal models of epilepsy

Bilateral transplantation of MGE
cells into the hippocampus of
TLE mice 2–4 weeks after SE

Bilateral and unilateral
transplantation into the STN of
rats

Bilateral transplantation of
striatal progenitors into
hippocampus at 4 days
post-SE after treatment with
FGF-2 and caspase inhibitor.

Bilateral transplantation into the
SN of rats after seven ADT
determinations

Bilateral injection into the
occipital cortices of P0 mice

Location and timing of
transplantation

• The transplanted cells displaying extensive migration developed into
functional GABAergic interneurons that integrated into the neural
circuitry of host brain
• The grafted cells presented presynaptic machinery for releasing
GABA to inhibit host neurons as well as postsynaptic machinery for
receiving excitatory synaptic inputs from host neurons in the
hippocampus
• The seizure frequency was significantly reduced following hESC
derived-MGE cell transplantation
• Behavioral abnormalities such as hyperactivity, aggressiveness and
cognitive deficits were alleviated after MGE cell grafting

• Viable transplanted cells were visible to the end of the experiments
• The anticonvulsant effects could be induced by bilateral/unilateral
transplantation of GABA-producing cells into the STN, while such
effects were not able to be induced by transplantation of control
cells or grafting outside the STN
• Grafting into STN caused more pronounced anticonvulsant effects
than grafting into SNr

• 9–12 months after grafting, the frequency of spontaneous recurrent
motor seizures was 67–89% less than epilepsy-only and sham
grafting control groups
• Graft cell survival equivalent to 33% of transplanted cells
• ∼69% of the grafted cells differentiated into various subclasses of
GABAergic neurons
• No effects on aberrant MFS.

• The implanted neurons survived up at least to the end of the
experiments
• A significant increase in ADT was observed in the rats with
GABAergic grafts in the SN, which also displayed a marked
reduction in the severity of seizures
• This anticonvulsant effect did not relate to any adverse effects
although it was not long-lasting

• The frequency and duration of AE episodes were reduced and
mortality was lowered after transplantation of MGE cells
• Despite a low yield of integration after grafting, 93 ± 4% of the
integrated cells were GABAergic
• The defective cortical network activity was significantly altered by
MGE grafting

Results of transplantation

ADT, afterdischarge threshold; AE, absence epilepsy; DG, dentate gyrus; E, embryonic day; FGF-2, fibroblast growth factor-2; GFP, green fluorescent protein; hGAD, human glutamic acid decarboxylase; LEC, lateral
entorhinal cortex; LGE, lateral ganglionic eminence; MES, maximum electroconvulsive shock; MFS, mossy fiber sprouting; MGE, medial ganglionic eminence; P, postnatal day; PTZ, pentylenetetrazole; SE, status
epilepticus; SN, substantia nigra; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; TLE, temporal lobe epilepsy.

Human

Rat

Hattiangady
et al., 2008

Cunningham
et al., 2014

Rat

Löscher
et al., 1998

Rat

Mouse

Hammad
et al., 2014

Handreck
et al., 2012

Cell
source

Reference

TABLE 1 | Continued
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FIGURE 1 | Schematic illustration of cell therapies for epilepsy. (A) Transplantation of GABAergic interneurons/progenitors from mouse/rat embryos or
human/mouse PSCs has been studied in different rodent models of epilepsy. (B) Human PSC-derived GABAergic interneurons/progenitors would be a promising
cell source for transplantation to target epileptic foci in humans though the challenges exist.

relatively undisturbed state, and can also be truly restorative in
nature.

as hyperactivity, aggressiveness and cognitive deficits. This
study provides proof-of-concept that GABAergic interneuron
progenitors derived from human PSCs could provide a valuable
and unlimited cell source for cell transplantation to treat
intractable seizures.
There are various benefits of cell-based therapies for
epilepsy, in comparison to more traditional treatment methods.
Functionally distinct subtypes of GABAergic interneurons or
other types of neurons could be generated and implanted into
specific regions of the host brain (Bjarkam et al., 2009), thus
obviating many of the adverse systemic side effects caused
by AEDs. Furthermore, because developing neurons may be
able to integrate into host brain circuits, they could provide
synaptic inhibition on demand in an activity-dependent manner
and circumvent issues associated with taking medications
regularly and maintaining constant drug dosage. A selfregulating therapeutic system of grafted interneurons, activated
by host excitatory neurons that releases GABA synaptically
during periods of heightened hyperexcitability (Cunningham
et al., 2014) would render the need to wear devices to detect
and manage seizures obsolete. While resection of the seizure
focus has been used as a last-resort interventional measure for
refractory epilepsy, it carries the risk of surgical damage to
otherwise healthy neural tissues, along with resultant aftereffects,
such as morbidity and even permanent dysfunction (Jobst and
Cascino, 2015). Although high-precision stereotactic stem cell
transplantation would still be associated with neurosurgical risks,
it has the advantage of leaving functional neural tissue in a
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CHALLENGES AND OPPORTUNITIES
Transplantation of GABAergic interneurons/progenitors from
mouse/rat embryos or mouse PSCs has been widely studied in the
rodent models of epilepsy, and the initial results of human PSCderived GABAergic progenitor transplantation are encouraging
(Cunningham et al., 2014), offering hope for the realization of
cell-based therapy for epilepsy (Figure 1). Nonetheless, some
issues need to be addressed before transition into clinical use.
First, to better control seizures, basic mechanisms underlying
seizure suppression have to be futher explored. Designer
receptors exclusively activated by designer drugs (DREADDs)
can be used to dissect the neural circuits responsible for different
behaviors by activating or inhibiting specific neurons through
modulating G protein-coupled receptor activity (Whissell et al.,
2016). With this approach, the relationship between the activities
of engrafted neurons and the seizure phenotype can be
investigated in epilepsy models. Additionally, utilization of
DREADDs could help neuroscientists determine whether seizure
suppression is a result of the synaptic inhibition provided by
the engrafted cells or other anticonvulsant mechanisms (e.g.,
graft release of neurotrophic factors including glial cell-linederived neurotrophic factor) (Li et al., 2002; Simonato et al., 2006;
Hattiangady and Shetty, 2011; Shetty, 2012).
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Second, the safety of the cell preparations should be critically
evaluated before transplantation. Teratoma formation is closely
correlated to the persistence of proliferating or undifferentiated
PSCs after transplantation (Blum and Benvenisty, 2008; Miura
et al., 2009; Germain et al., 2012). Thus, for therapeutic purposes,
isolating the optimal cell population before implantation will be
critical for ensuring patient safety. Purifying the desired cell type
by fluorescence activated cell sorting (FACS) is one approach that
has been used successfully to reduce teratoma formation after
transplantation (Chung et al., 2006). The ideal cell types should be
highly migratory for optimal integration into host brain circuity
after transplantation. In addition to the prevention of tumor
formation, optimal cell density needs to be carefully determined
to prevent potential adverse neuropsychiatric effects in vivo.
None of the studies reported adverse effects of interneuron
transplantation so far in the rodents. Instead, there are plethora
of studies with interneuron transplantation that have shown
functional benefits not only in seizure reduction but also
in normalization of other behavioral abnormalities such as
cognition, memory, aggressive behavior and motor symptoms
in various animal models of brain disease such as epilepsy,
schizophrenia and Parkinson’s (Martínez-Cerdeño et al., 2010;
Liu et al., 2013b; Cunningham et al., 2014; Southwell et al.,
2014; Donegan et al., 2016). Interestingly, it has been shown
that the inhibition following cortical interneuron transplantation
reaches a plateau with relatively low numbers of grafted cells
(Southwell et al., 2014), suggesting that a larger number of
cortical interneurons are not likely to cause abnormal behavior
after cell transplantation. Still, the neuropsychiatric side effects
need to be carefully examined in depth in the primate model
that more closely matches the higher cognitive functions of the
human brain. To further ensure the safety of grafts, chemogenetic
modulation or suicide gene regulation may be incorporated to
provide the ability to eliminate any potential adverse effects
caused by the transplanted cells (Tey et al., 2007; Chen et al.,
2016).
Third, the optimal site for interneuron transplantation must
be determined, which is especially important when the seizure
focus can not be clearly identified or there are multiple foci.
As summarized above, seizure suppression has been observed
following transplantation of interneurons to the seizure focus
(Hunt et al., 2013; Henderson et al., 2014), but in addition,
other brain regions such as SN or STN were shown to be
effective sites for in modulating seizure activity in rat epilepsy
models (Löscher et al., 1998; Handreck et al., 2012). Moreover,
interneuron transplantation into part of epileptic brain region,
providing limited innervation of the seizure focus, has also been
found to reduce seizures or elevated seizure thresholds (Baraban
et al., 2009; Calcagnotto et al., 2010; Hammad et al., 2014). Thus,
the optimal sites of cell transplantation and distribution of the

transplanted cells need to be carefully compared and determined
for each seizure disorder.
Fourth, the process of maturation and differentiation in
human PSC-derived MGE progenitor cells is lengthy, and
appears to follow their innate in vivo time line in the
human embryos (Nicholas et al., 2013). Developing interneurons
integrate well into adult epileptic circuitry, receive excitatory
inputs from the host brain, inhibit host neurons by releasing
GABA and ameliorate seizures prior to attaining fully mature
electrophysiological properties (e.g., Fast spiking) (Cunningham
et al., 2014), but more efficient approaches need to be developed
to speed up the maturation of transplanted cells with the purpose
of accelerating the development of seizure suppression after
grafting.
Finally, to overcome the requirement that recipients of
grafts undergo long-term immunosuppression to prevent graft
rejection, personalized stem cell treatments have been proposed.
Personalized cell therapy uses the patient’s own iPSCs to generate
needed neurons, however, this approach could easily cost
hundreds of thousands of dollars (Lee et al., 2000). To overcome
the prohibitive cost issue associated with personalized cell
therapy, tissue banks could be established for human leukocyte
antigen (HLA)-matching donor cells. This is an achievable goal
for reducing costs and overcomes hazards associated with longterm immunosuppression and graft rejection (Taylor et al., 2012;
Solomon et al., 2014; Cyranoski, 2017).
As the mechanisms for seizure control by interneuron grafts
become better understood, and our ability to regulate the
integration, proliferation, and function of engrafted cells becomes
more refined, we envision a time in the future when patients
with intractable seizure disorders may consider hPSC-based
interneuron transplantation therapy as a safe and effective
treatment option.
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